RT Journal Article
SR Electronic
T1 Inferring the differences in incubation-period and generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.02.22277186
DO 10.1101/2022.07.02.22277186
A1 Park, Sang Woo
A1 Sun, Kaiyuan
A1 Abbott, Sam
A1 Sender, Ron
A1 Bar-on, Yinon
A1 Weitz, Joshua S.
A1 Funk, Sebastian
A1 Grenfell, Bryan T.
A1 Backer, Jantien A
A1 Wallinga, Jacco
A1 Viboud, Cecile
A1 Dushoff, Jonathan
YR 2022
UL http://medrxiv.org/content/early/2022/07/05/2022.07.02.22277186.abstract
AB Estimating the differences in the incubation-period, serial-interval, and generation-interval distributions of SARS-CoV-2 variants is critical to understanding their transmission and control. However, the impact of epidemic dynamics is often neglected in estimating the timing of infection and transmission—for example, when an epidemic is growing exponentially, a cohort of infected individuals who developed symptoms at the same time are more likely to have been infected recently. Here, we re-analyze incubation-period and serial-interval data describing transmissions of the Delta and Omicron variants from the Netherlands at the end of December 2021. Previous analysis of the same data set reported shorter mean observed incubation period (3.2 days vs 4.4 days) and serial interval (3.5 days vs 4.1 days) for the Omicron variant, but the number of infections caused by the Delta variant decreased during this period as the number of Omicron infections increased. When we account for growth-rate differences of two variants during the study period, we estimate similar mean incubation periods (3.8–4.5 days) for both variants but a shorter mean generation interval for the Omicron variant (3.0 days; 95% CI: 2.7–3.2 days) than for the Delta variant (3.8 days; 95% CI: 3.7–4.0 days). We further note that the differences in estimated generation intervals may be driven by the “network effect”—higher effective transmissibility of the Omicron variant can cause faster susceptible depletion among contact networks, which in turn prevents late transmission (therefore shortening realized generation intervals). Using up-to-date generation-interval distributions is critical to accurately estimating the reproduction advantage of the Omicron variant.Significance Recent studies suggest that individuals infected with the Omicron variant develop symptoms earlier (shorter incubation period) and transmit faster (shorter generation interval) than those infected with the Delta variant. However, these studies typically neglect population-level effects: when an epidemic is growing, a greater proportion of current cases were infected recently, biasing us toward observing faster transmission events. Accounting for this dynamical bias, we find that Omicron infections from the Netherlands at the end of December 2021 had similar incubation periods, but shorter generation intervals, compared to Delta infections from the same period. Shorter generation intervals of the Omicron variant might be due to its higher effective reproduction number, which can cause faster local susceptible depletion around the contact network.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJD was supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Michael G. DeGroote Institute for Infectious Disease Research. JSW acknowledges support from the Army Research Office W911NF1910384 and the Ile de France region via the Chaires Blaise Pascal program. JW and JB has received funding from European Union's Horizon 2020 research and innovation programme---project EpiPose, Epidemic intelligence to Minimize COVID-19's Public Health, Societal and Economical Impact (grant agreement number 101003688). SF was supported by the Wellcome Trust (grant no. 210758/Z/18/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the funding agencies, the National Institutes of Health, or the U.S. Department of Health and Human Services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are stored in a publicly available GitHub repository (https://github.com/parksw3/omicron-generation).